NCT00984854 is a Phase 1 clinical trial of Juvidex in Cicatrix, sponsored by Renovo.

Who is sponsoring NCT00984854?

NCT00984854 is sponsored by Renovo.

What drugs are being tested in NCT00984854?

Interventions in NCT00984854: Juvidex, Juvidex, Juvidex, Juvidex, Juvidex, Juvidex, Placebo.

What condition does NCT00984854 study?

NCT00984854 studies Cicatrix, Re-epithelialisation.

Is NCT00984854 still recruiting?

NCT00984854 is currently completed. Last updated 24 September 2009.

Last reviewed 2009-09-24 · How we verify

NCT00984854

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial to Investigate the Clinical Safety, Local Toleration, and Systemic Pharmacokinetics of Repeated, Escalating Concentrations of Intradermal RN1004 to Wounds of Healthy Subjects.

Completed Phase 1 Last updated 24 September 2009

What this trial tests

Phase 1 trial testing Juvidex in Cicatrix in 70 participants. Completed in 1 July 2004.

Timeline

1 January 2004

Primary endpoint
1 July 2004

1 July 2004

Quick facts

Lead sponsor	Renovo
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	70
Start date	1 January 2004
Primary completion	1 July 2004
Estimated completion	1 July 2004
Sites	1 location across United Kingdom

Drugs / interventions tested

Juvidex — full drug profile →
Juvidex — full drug profile →
Juvidex — full drug profile →
Juvidex — full drug profile →
Juvidex — full drug profile →
Juvidex — full drug profile →
Placebo

Conditions studied

Cicatrix — all drugs for Cicatrix →
Re-epithelialisation — all drugs for Re-epithelialisation →

Sponsor

Renovo — full company profile →

Who can join

Adults 18 to 45, any sex, with Cicatrix or Re-epithelialisation. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To assess the safety and local toleration of various dose levels of Juvidex (RN1004) injected intradermally in healthy volunteers.
Time frame: 22 Days

Sponsor's own description

The purpose of this study was to investigate the safety and toleration of various doses of intradermal Juvidex (mannose-6-phosphate) administered to punch biopsies of normal subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Novel pharmacotherapy for burn wounds: what are the advancements.
Hamblin MR. · · 2019 · cited 17× · PMID 30517046 · DOI 10.1080/14656566.2018.1551880

Verify or expand the search:

Other recruiting trials for Cicatrix

Currently open trials in the same condition.

NCT06122090 — Treatment of Hypopigmented Scars With Bimatoprost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00984854 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Renovo
Last refreshed: 24 September 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00984854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing